<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216436</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00019239</org_study_id>
    <nct_id>NCT01216436</nct_id>
  </id_info>
  <brief_title>Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma</brief_title>
  <official_title>Phase 1 Study of Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our proposed study is designed to test the safety of a new vaccine against melanoma. The
      induction of immune activity against cancers such as melanoma is a promising approach to
      cancer treatment, but to date, only a few clinically significant immune responses have been
      seen following vaccine therapy. This is an important problem, since there are very limited
      treatment options for patients with metastatic melanoma (melanoma that has spread to lymph
      nodes and organs).

      Studies suggest that monoclonal antibodies (mAbs) that block inhibitory receptors on immune
      cells can enhance the immune responses against cancer, but the intravenous injection of such
      mAbs has caused severe side effects in animals and humans. In our laboratory, we have
      developed a method to deliver mAbs and other proteins that block such inhibitory receptors
      locally at the site where immune responses against melanoma proteins are stimulated by
      vaccination, enhancing anti-melanoma immunity while avoiding the side-effects associated with
      intravenous injection of these immune modulators. This is achieved by loading dendritic
      cells, a type of immune cell, with RNA that encodes the immune modulator. The RNA-loaded
      dendritic cells then make the immune modulatory proteins and release them locally. By mixing
      these dendritic cells with additional dendritic cells loaded with melanoma proteins, the
      immune modulators are released at the site where anti-melanoma immune cells are stimulated.

      In this phase I trial, subjects with metastatic melanoma will undergo the process of
      leukapheresis, in which white blood cells are removed from the body. Monocytes, a type of
      immune cell, will then be purified from the white blood cells and cultured under conditions
      that will change them into dendritic cells. Half of these dendritic cells are then loaded
      with melanoma antigen RNA, which will lead to the production of melanoma antigen proteins
      within the dendritic cells. The remaining half of the dendritic cells will be either
      untreated or loaded with RNA encoding immune modulators so that these dendritic cells will
      release immune modulators at the site of vaccination. These dendritic cells will be mixed
      with the melanoma antigen-loaded dendritic cells and injected as a vaccine into lymph nodes.
      Each subject will receive six weekly injections of their own dendritic cells. Safety and
      toxicity will be closely monitored. In addition, immune responses against melanoma, as well
      as clinical responses, will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A variety of trials of immunotherapy in metastatic melanoma have clearly demonstrated that
      immune responses against melanoma can be induced, but only a few patient have responded
      clinically, suggesting that new strategies to enhance anti-cancer immune responses are
      needed. Most of these immunotherapy trials have focused on antigen delivery and providing
      stimulatory antigen-specific signals to T cells. However, the induction of antigen-specific T
      cell-mediated immune responses is regulated not only by stimulatory signals, but also by
      inhibitory receptor-mediated signals. Studies have demonstrated that administering mAbs
      targeting such immune-modulating receptors on T cells enhances vaccine-induced anti-tumor
      immunity, suggesting that such an approach might improve the efficacy of clinical cancer
      vaccines. However, systemic administration such mAbs has been associated with severe,
      sometimes fatal, autoimmunity. We have developed an approach for targeted delivery of such
      immune modulatory proteins and mAbs, using immune modulator RNA-transfected dendritic cells
      (DC), to sites where anti-tumor T cells are induced. Our preliminary studies indicate that
      this approach may eliminate the adverse effects associated with systemic administration
      immune modulators, while also enhancing vaccine-induced immune responses.

      Therefore, the objective of this proposed Phase I immunotherapy trial is to determine the
      safety and obtain preliminary data on the efficacy of vaccination of human subjects with
      melanoma tumor associated antigen (TAA) RNA-transfected mature monocyte-derived DC
      coadministered with additional untransfected DC (Study Arm A), DC transfected with RNA
      encoding a soluble GITR-L fusion protein (Study Arm B), DC transfected with RNA encoding the
      humanized heavy and light chains of an antagonistic anti-CTLA-4 mAb (Study Arm C), or DC
      transfected with combined GITR-L and anti-CTLA-4 mAb RNA (Study Arm D). All study subjects
      will undergo leukapheresis for collection of peripheral blood mononuclear cells (PBMC) and
      purified monocytes will be cultured with the cytokines GM-CSF and IL-4 to produce immature
      DC. After the induction maturation with a standard cytokine cocktail, half of the DC will
      then be transfected with RNA encoding melanoma TAAs MART, tyrosinase, and gp100, and MAGE-3,
      while the remaining half of the DC will be either untransfected (Study Arm A) or will be
      transfected with immune modulator RNA (Study Arm B, C, and D). DC will be cryopreserved.
      Subjects will then be immunized with these DC, weekly for six intranodal injections. For each
      subject, safety and toxicity will be assessed, and anti-tumor immune responses will be
      measured.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The PI retired
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>A minimum of 6 months</time_frame>
    <description>Safety and Tolerability will be assessed for all subjects during the vaccination period and then regularly during the post-vaccination period. All subjects will then be followed clinically as would be done any subject with melanoma for a total of 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular anti-melanoma immune responses will be assessed</measure>
    <time_frame>A minimum of 4 months</time_frame>
    <description>T cells from blood collected after each vaccination and following the full course of vaccination will be assessed for melanoma antigen-specificity using Interferon-gamma Elispot and cytotoxicity assays. Immune responses will be assessed following each vaccination and then will continue to be assessed until anti-melanoma immune responses return to baseline levels.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Vaccine plus untransfected DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine plus GITRL RNA DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine plus antiCTLA4 RNA DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine plus GITRL/ antiCTLA4 RNA DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with RNA-transfected mature autologous DC</intervention_name>
    <description>Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals</description>
    <arm_group_label>Vaccine plus untransfected DC</arm_group_label>
    <arm_group_label>Vaccine plus GITRL RNA DC</arm_group_label>
    <arm_group_label>Vaccine plus antiCTLA4 RNA DC</arm_group_label>
    <arm_group_label>Vaccine plus GITRL/ antiCTLA4 RNA DC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed metastatic melanoma

          -  Karnofsky performance status greater than or equal to 70%.

          -  Estimated life expectancy &gt; 6 months.

          -  Age &gt; 17 years.

          -  Adequate hematologic function with:

               -  WBC &gt;= 3000 mm3

               -  hemoglobin &gt;= 9 mg/dl

               -  platelets &gt;= 100,000/mm3

          -  Adequate renal and hepatic function with:

               -  serum creatinine &lt; 2.5 mg/dl

               -  bilirubin &lt; 2.0 mg/dl

               -  AST/SGOT &lt; 70 U/L

               -  ALT/SGPT &lt; 70 U/L

               -  Alkaline Phosphatase â‰¤ 135 U/L

          -  Ability to understand and provide signed informed consent that fulfills Institutional
             Review Board guidelines.

          -  Ability to return to Duke University Medical Center for adequate follow-up as required
             by this protocol.

        Exclusion Criteria:

          -  Subjects undergoing concurrent chemotherapy, radiation therapy, or immunotherapy will
             be excluded.

          -  The subject has previously irradiated, surgically treated, or newly diagnosed central
             nervous system (CNS) metastases will be excluded (Pre-enrollment head CT is not
             required if not indicated by clinical signs or symptoms).

          -  Subjects with a history of autoimmune disease such as, but not restricted to,
             inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis,
             scleroderma, or multiple sclerosis will be excluded.

          -  Subjects with serious concurrent chronic or acute illness such as pulmonary (asthma or
             COPD), cardiac (NYHA class III or IV) or hepatic disease, or other illness considered
             by the principal investigator to constitute an unwarranted high risk for
             investigational drug administration will be excluded.

          -  Subjects with medical or psychological impediment to probable compliance with the
             protocol will be excluded.

          -  Subjects with concurrent second malignancy other than melanoma or non-melanoma skin
             cancer will be excluded. In the event of prior non-melanoma malignancies treated
             surgically, the subject must be considered NED (no evidence of disease) for a minimum
             of 3 years prior to enrollment.

          -  Presence of an active acute or chronic infection, including symptomatic urinary tract
             infection, HIV (as determined by ELISA and confirmed by Western Blot) or viral
             hepatitis (as determined by HBsAg and Hepatitis C serology) will lead to subject
             exclusion.

          -  Subjects receiving steroid therapy (or other immunosuppressive agents such as
             azathioprine or cyclosporine A) are excluded on the basis of potential immune
             suppression.

          -  Subjects with inadequate peripheral vein access to undergo leukapheresis will be
             excluded.

          -  Female subjects with a positive pregnancy test, as well as those who have not
             previously undergone hysterectomy and/or bilateral oophorectomy and are unwilling to
             utilize a medically approved form of contraception, from the time of enrollment until
             6 weeks after the final immunization, will be excluded.

          -  Male subjects, not previously surgically sterilized, who are unwilling to use a condom
             with spermicide during any sexual activity occurring over the entire immunization
             period and for the 6 weeks that immediately follow the final immunization will be
             excluded.

          -  Subjects with a documented history of severe allergic reaction to beta-lactams, eggs
             or soy products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott K Pruitt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, Tyler DS, Dannull J, Nair S. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol. 2011 Dec;41(12):3553-63. doi: 10.1002/eji.201141383. Epub 2011 Oct 26.</citation>
    <PMID>22028176</PMID>
  </reference>
  <reference>
    <citation>Boczkowski D, Lee J, Pruitt S, Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther. 2009 Dec;16(12):900-11. doi: 10.1038/cgt.2009.39. Epub 2009 Jun 5.</citation>
    <PMID>19498460</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>dendritic cell</keyword>
  <keyword>GITR-ligand</keyword>
  <keyword>CTLA-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

